Blood Res 2014; 49(1):
Published online March 31, 2014
https://doi.org/10.5045/br.2014.49.1.36
© The Korean Society of Hematology
1Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
2Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
3Department of Internal Medicine, Gangneung Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Correspondence to : Correspondence to Cheolwon Suh, M.D., Ph.D. Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul 138-736, Korea. Tel: +82-2-3010-3209, Fax: +82-2-3010-6961, csuh@amc.seoul.kr
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Primary mediastinal large B-cell lymphoma (PMBL) is a distinct subtype of non-Hodgkin lymphoma, which has no consensus for its ideal treatment or prognosis.
We reviewed the clinicopathologic features and clinical outcomes of 25 PMBL cases diagnosed at a single institution between 1993 and 2009 and compared them with 588 cases of non-mediastinal, diffuse large B-cell lymphoma (DLBCL, control group) diagnosed during the same period.
Thirteen (52.0%) PMBL patients had Ann Arbor stage III or IV disease, and 10 (40.0%) had B symptoms. Thirteen (52%) PMBL patients were classified as high-intermediate/high-risk according to the International Prognostic Index. There was a significant prevalence of young (median: 31 years; range, 15-78 years;
Compared to patients with non-mediastinal DLBCL, Korean patients with PMBL are predominantly young women with bulky disease and high LDH levels but with no significant difference in survival.
Keywords Lymphoma, B cell, PMBL, Prognosis, Treatment
Blood Res 2014; 49(1): 36-41
Published online March 31, 2014 https://doi.org/10.5045/br.2014.49.1.36
Copyright © The Korean Society of Hematology.
Heui June Ahn1,3,#, Dok-Hyun Yoon1,#, Shin Kim1, Kyoungmin Lee1, EunHee Kang1, Jooryung Huh2, Chan-Sik Park2, and Cheolwon Suh1*
1Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
2Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
3Department of Internal Medicine, Gangneung Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Correspondence to: Correspondence to Cheolwon Suh, M.D., Ph.D. Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul 138-736, Korea. Tel: +82-2-3010-3209, Fax: +82-2-3010-6961, csuh@amc.seoul.kr
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Primary mediastinal large B-cell lymphoma (PMBL) is a distinct subtype of non-Hodgkin lymphoma, which has no consensus for its ideal treatment or prognosis.
We reviewed the clinicopathologic features and clinical outcomes of 25 PMBL cases diagnosed at a single institution between 1993 and 2009 and compared them with 588 cases of non-mediastinal, diffuse large B-cell lymphoma (DLBCL, control group) diagnosed during the same period.
Thirteen (52.0%) PMBL patients had Ann Arbor stage III or IV disease, and 10 (40.0%) had B symptoms. Thirteen (52%) PMBL patients were classified as high-intermediate/high-risk according to the International Prognostic Index. There was a significant prevalence of young (median: 31 years; range, 15-78 years;
Compared to patients with non-mediastinal DLBCL, Korean patients with PMBL are predominantly young women with bulky disease and high LDH levels but with no significant difference in survival.
Keywords: Lymphoma, B cell, PMBL, Prognosis, Treatment
Kaplan-Meier curves showing progression-free survival (
Table 1 . Clinical characteristics and initial treatment regimens of 588 patients with DLBCL and 25 patients with PMBL..
Abbreviations: DLBCL, diffuse large B-cell lymphoma; PMBL, primary mediastinal large B-cell lymphoma; PS, performance status; LDH, lactate dehydrogenase; IPI, International Prognostic Index; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisolone; R-CHOP, CHOP plus rituximab..
Table 2 . Clinical courses of the 25 PMBL patients..
a)One patient received consolidation RT followed by ASCT..
Abbreviations: PMBL, primary mediastinal large B-cell lymphoma; CR, complete response; RT, radiotherapy; ASCT, autologous stem cell transplantation; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisolone; R-CHOP, CHOP plus rituximab; Vanderbilt, cyclophosphamide, etoposide, vincristine, bleomycin, methotrexate, doxorubicin, and prednisolone; ESHAP, etoposide, methylprednisolone, cytarabine, and cisplatin..
Table 3 . Univariate analysis for progression-free survival and overall survival in patients with PMBL..
Abbreviations: PMBL, primary mediastinal large B-cell lymphoma; PFS, progression-free survival; OS, overall survival; PS, performance status; LDH, lactate dehydrogenase; IPI, International Prognostic Index; SVC, superior vena cava..
Jae Ho Jeong, Shin Kim, Jeong Eun Kim, Dok Hyun Yoon, Sang-Wook Lee, Jooryung Huh, and Cheolwon Suh
Blood Res 2017; 52(2): 125-129Sung-Hoon Jung, Youngil Koh, Min Kyoung Kim, Jin Seok Kim, Joon Ho Moon, Chang-Ki Min, Dok Hyun Yoon, Sung-Soo Yoon, Je-Jung Lee, Chae Moon Hong, Ka-Won Kang, Jihyun Kwon, Kyoung Ha Kim, Dae Sik Kim, Sung Yong Kim, Sung-Hyun Kim, Yu Ri Kim, Young Rok Do, Yeung-Chul Mun, Sung-Soo Park, Young Hoon Park, Ho Jin Shin, Hyeon-Seok Eom, Sang Eun Yoon, Sang Mee Hwang, Won Sik Lee, Myung-won Lee, Jun Ho Yi, Ji Yun Lee, Ji Hyun Lee, Ho Sup Lee, Sung-Nam Lim, Jihyang Lim, Ho-Young Yhim, Yoon Hwan Chang, Jae-Cheol Jo, Jinhyun Cho, Hyungwoo Cho, Yoon Seok Choi, Hee jeong Cho, Ari Ahn, Jong Han Choi, Hyun Jung Kim and Kihyun Kim
Blood Res 2025; 60():Hyewon Lee
Blood Res 2023; 58(S1): S66-S82
Kaplan-Meier curves showing progression-free survival (